BIt's Closing Bell, and Marvell is reportedly weighing an eighty-three billion dollar bet on AI optics. We're going to fight about whether it's genius or dilution.
BPlus Eli Lilly at records, Bitcoin losing eighty thousand, and a date mistake from Cointelegraph we'll fix.
BBloomberg reported Marvell's in advanced talks to buy Lumentum. All-stock, could be announced as soon as next week.
BLumentum jumped seventeen percent after hours. Marvell fell fourteen. Unusual Whales on X says a trader bought a thousand put contracts at the ask — nineteen point six million dollars.
AQuick correction: that specific nineteen point six million block doesn't show up anywhere I can confirm. What was reported was a smaller three point one million in Lumentum puts.
BEven that is a bearish bet on a company about to get acquired. Why would anyone buy puts on the target of an acquisition?
ABecause deals fall through. Or the premium shrinks. But my real problem is the price: Marvell reportedly paying eighty-three billion in stock, and its shareholders feel it — fourteen percent down today.
BThat drop is the mechanics of an all-stock deal! The acquirer always dips. The question is whether the assets are worth it.
AAre they? Marvell needs indium-phosphide optical parts — copper's hitting a wall in AI data centers. Lumentum's sold out through early 2029. Can't meet seventy percent of demand.
BExactly! Nvidia put two billion dollars into Lumentum earlier this year. This is the scarcest part of the AI buildout. Marvell had to do this.
AHad to? Or got pushed? Bernstein says a deal this size probably can't even be funded in cash. That's not conviction, that's a forced hand.
BNo, no — all-stock is the smart part. Raymond James said it avoids interest costs, so earnings dilute less. You'd rather Marvell lever up with debt at these rates? Come on.
AI'd rather they not hand over a big chunk of the company for a laser maker where they'd likely sell the pluggable module business anyway. Buy the thing, then sell a piece.
BThat's normal consolidation. The core — indium-phosphide tech — is what AI clusters are starving for. Lumentum's CEO says they can't even meet demand. Marvell's taking that scarcity off the board.
AThe market isn't convinced. A put bet — or the smaller three million one — says someone thinks this breaks or the premium collapses.
BSomeone's shorted every good deal ever. The real question: do you want AI systems with copper bottlenecks, or optics? I say optics.
AHere's the overlooked part, though — Marvell's already a Lumentum customer. They've seen these supply chain bottlenecks up close. This isn't a cold spreadsheet deal.
BRight. And Lumentum's the rare company actually sold out in AI. The scarcity's real, not a pitch.
AI'll give you that. Still, executing an eighty-three billion stock deal isn't a walk. We'll see if Bloomberg's timing holds next week.
ADifferent corner of the market: Eli Lilly caught a bid, all-time highs around thirteen sixty-five a share.
AUnusual Whales posted the breakdown on X. Mounjaro up sixty-five percent, Zepbound up forty-nine, and a raised 2026 guide to ninety-one, ninety-two billion.
BThose are monster numbers for a company that was just a drugmaker a decade ago.
AI couldn't confirm those exact figures, but the stock did hit a record on strong GLP-1 drug sales. The story's intact even if the post's numbers are loose.
BLilly's become one of the biggest companies on the planet off essentially two drugs — Mounjaro and Zepbound. Either amazing or terrifying, take your pick.
AIt's both. At over thirteen hundred a share, it's priced for perfection. One bad clinical read and you're explaining yourself for a year.
BThat's every pharma name with a hit drug. But Lilly keeps executing. I'm not telling anyone to buy it — just saying the tape speaks.
AThe tape speaks, but I'd want to know what it says at thirteen hundred versus nine hundred. Valuation still matters.
BSpeaking of the tape — crypto's telling a different story today. Green Wick Energy on X says Bitcoin briefly dropped below eighty thousand.
AUnverified, but the direction's ugly. The broader market's struggling even with fresh ETF inflows, like the post says.
BThe ETF flows are whipsawing. Roar Steel posted a three hundred one million dollar weekly inflow ending a two-week losing streak. But that came after hundreds of millions in outflows.
AI can't verify that inflow number either. But when flows flip positive and price still can't hold eighty thousand, bigger sellers are out there.
BCrypto's tied to tech right now, and tech was mixed today. Bitcoin's just the highest-beta expression of the same nervous trade.
BAnd here's a sign of where institutions are heading — Cointelegraph also posted that ICE, the NYSE's parent, took a stake in a crypto derivatives firm and plans a US-regulated perpetuals market built on Hyperliquid.
AUnverified, but if true, that's the big end of Wall Street moving onto crypto rails. The NYSE's parent building on a decentralized platform — that's a headline.
BFrom crypto to the people who set rates: a Cointelegraph post on Telegram says Christine Lagarde is stepping down as ECB president on February seventh next year.
AThe date's wrong. Lagarde's term started November first of 2019 and runs eight years. It ends October thirty-first, 2027.
BSo Cointelegraph missed by about nine months.
ACorrect. No credible sign of an early exit. The real date's the end of October next year.
BTiming matters. The ECB president sets the tone on eurozone rates. If you're tracking cuts, it's October, not February.
AAnd Amazon reports after the bell. We'll have those numbers the second they hit.
BBig test for the AI trade. We're back with it right after the close.